Search Results for keywords:"Pharmaceutical Products"

PCI Pharma Services, operating within Foreign-Trade Zone (FTZ) 176 in Rockford, Illinois, submitted a proposal on behalf of Tricida Inc. for production activities. The FTZ Board reviewed the notification under its regulations and invited public comments through the Federal Register. On February 11, 2021, the FTZ Board decided no further review was needed and authorized the proposed production activity. This decision adheres to the regulations of the FTZ Act and specific FTZ Board rules.

AbbVie, Inc. has submitted a request to the Foreign-Trade Zones (FTZ) Board to expand its production activities at facilities in North Chicago and Lake County, Illinois. The company wants permission to produce a new pharmaceutical product and include a foreign material, specifically the active ingredient Ibrutinib, which has a duty rate of 6.5%. If approved, AbbVie could avoid paying certain customs duties on materials used in exports, and there are opportunities for reduced customs duties on waste components. Public comments on this request are open until March 15, 2021, and more details are available on the FTZ Board's website.

Lilly del Caribe, Inc. has submitted a request to the Foreign-Trade Zones (FTZ) Board for new production activities at its facility in Carolina, Puerto Rico. This request involves using specific foreign materials, including orforglipron, which may require certain duty payments based on their origin. Public comments on the proposed production activity are invited until March 24, 2025. The proposed activities and materials need to be approved by the Board and are required to be entered into the FTZ in privileged foreign status due to international trade regulations.

Merck, Sharp & Dohme LLC submitted a proposal to the Foreign-Trade Zones Board to conduct production activities at its facility in Rahway, New Jersey. The request was reviewed according to the Board's regulations, and the public was invited to comment. On January 16, 2024, the Board decided no further review was needed, and the production activity was authorized under existing regulations. The notification was officially documented on January 16, 2025.

Merck, Sharp & Dohme LLC submitted a request to the Foreign-Trade Zones (FTZ) Board on October 18, 2024, to start production activities at its facility in Rahway, New Jersey, which is part of FTZ Subzone 49Y. The FTZ Board reviewed this request and announced in the Federal Register that public comments on the activity were welcome. On February 18, 2025, the FTZ Board decided that no further review was necessary and approved the proposed production activities, as long as they comply with FTZ regulations. This authorization was communicated to the applicant on the same day.